Pfizer (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Utrecht University荷兰15
2. Pfizer (United Kingdom)英国13
3. London School of Hygiene & Tropical Medicine英国12
4. Novartis (Switzerland)瑞士12
5. European Medicines Agency荷兰10
6. Agencia Española de Medicamentos y Productos Sanitarios西班牙8
7. GlaxoSmithKline (United Kingdom)英国8
8. Sanofi (United States)美国8

按月发文

逐年被引

最新文献

1. 1
   Novel Recruitment, Data Collection, and Safety Reporting Methods in the Era of COVID ‐19: Design of a Post‐Emergency Use Authorization COVID ‐19 Vaccination Safety‐Surveillance StudyPharmacoepidemiology and Drug Safety20260
2. 2
   Cost effectiveness and public health impact of PCV20 among adults in FranceBMC Public Health20260
3. 3
   Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in KoreaPharmacoepidemiology and Drug Safety20260
4. 4
   Development and Validation of an Endometrial Cancer Algorithm in US Claims DataPharmacoepidemiology and Drug Safety20261
5. 5
   Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in MongoliaBMC Public Health20260
6. 6
   Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer: A PodcastDrug Safety20250
7. 7
   Factors influencing Lyme borreliosis risk perception in Europe: a cross-sectional multi-country survey studyBMC Public Health20252
8. 8
   Interplay of physical activity, self-rated health, and life satisfaction among large-bodied adolescents in Europe and North America: analysis using clustered binary mixed effects logit modellingBMC Public Health20251
9. 9
   Identifying Maternal Conditions Leading to Gabapentinoid Prescriptions in Pregnancy Using Electronic Health Records from Six European Countries: A Contribution from the IMI ConcePTION ProjectDrug Safety20252
10. 10
    IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical TrialsDrug Safety20250

高被引文献

1. 1
   The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and ElaborationDrug Safety2024365
2. 2
   The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and StatementDrug Safety2024286
3. 3
   Trial designs using real‐world data: The changing landscape of the regulatory approval processPharmacoepidemiology and Drug Safety2019253
4. 4
   Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDsTherapeutics and Clinical Risk Management2015214
5. 5
   Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0Pharmacoepidemiology and Drug Safety2017182
6. 6
   Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and PsoriasisDrug Safety2016151
7. 7
   Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU ProjectPharmacoepidemiology and Drug Safety2015130
8. 8
   Selective estrogen receptor modulators in clinical practice: a safety overviewExpert Opinion on Drug Safety2015117
9. 9
   The Association of Health Literacy With Preventable Emergency Department Visits: A Cross‐sectional StudyAcademic Emergency Medicine201799
10. 10
    Recommendations for benefit–risk assessment methodologies and visual representationsPharmacoepidemiology and Drug Safety201678

主要发表期刊

研究主题